There's anti-aging hype. Then science shows real promise
Theres antiaging hype then hard science: ABC Four Corners finds wellness clinics and biohacking stalls racing ahead of human trials, while geroscience labs test autophagy drugs, thymus rejuvenation and partial epigenetic reprogramming. For now, physicians say exercise, nutrition and strong social ties remain the proven path to a longer, healthier life.
Key Takeaways
- Consumer anti-aging products often lack human clinical evidence, despite scientific-sounding marketing.
- Legitimate geroscience research targets shared aging pathways behind multiple chronic diseases.
- Startups are testing autophagy, thymus rejuvenation and epigenetic reprogramming in early human work.
- Fisetin, a senolytic “zombie cell” compound some researchers take, has strong mouse data but limited human trials.
- Exercise, diet and social connection still have the strongest evidence for healthy longevity.
The longevity boom is loud. Billionaire-backed startups chase huge valuations, biohackers sample red light, ozone and IV drips, and clinics sell NAD+ infusions to mostly healthy clients. An ABC Four Corners investigation separates that marketplace noise from lab work that may eventually matter for medicine.
Readers tracking longevity and biohacking will recognize the pattern: bold claims move faster than randomized human data.
What's driving the anti-aging hype right now?
At a New York biohacking conference, presenters pitched therapies from hydrogen inhalation to vibration plates and “exclusion zone” gels. Very few offerings had solid human evidence behind them, ABC reported.
In West Hollywood, Next Health markets MRI scans, blood panels, red light, hyperbaric oxygen, cryotherapy and plasma exchange. Founder Darshan Shah says clients often seek vitamin and NAD+ infusions after stressful weeks. Endocrinologist Professor Katherine Samaras called NAD boosters “a complete waste of money,” arguing lifestyle changes can support mitochondria more reliably. University of Sydney aging expert Professor Luigi Fontana said he has not seen randomized human trials proving NAD+ improves disease outcomes or even clear safety data.
In Australia, about 100 operators advertise IV drip clinics, recovery studios and telehealth peptides that sit in regulatory grey zones, with black-market products raising contamination risks.
Which longevity science shows real promise?
Geroscience treats cancer, heart disease, dementia and vision loss as diseases rooted in aging itself. Investor Karl Pfleger argues a true anti-aging drug could blunt many age-related conditions at once.
Retro Biosciences, backed by OpenAI founder Sam Altman with a reported $US180 million launch investment and a $US1.8 billion valuation, is running a first-in-human Alzheimer’s safety trial in Adelaide tied to cellular autophagy. Intervene Immune is exploring thymus rejuvenation after a small trial showed MRI signs of recovery, though researchers warn of autoimmune and cancer risks. Life Biosciences is testing partial epigenetic reprogramming in humans for glaucoma-related vision loss, co-founded with Harvard’s David Sinclair.
Do zombie-cell supplements live up to the buzz?
Separately, the New York Post spotlighted fisetin, a plant flavonoid sold as a budget senolytic aimed at “zombie” senescent cells that refuse to die and can drive inflammation. Mouse studies link chronic fisetin use to longer healthspan and lifespan, yet human evidence remains limited. The Post reported that Sinclair reportedly takes about 500 mg daily, underscoring how researchers sometimes self-experiment while consumer proof lags.
What actually works for healthy aging today?
While biotech races ahead, Fontana stresses calorie-restricted optimal nutrition, good food and physical exercise can markedly cut chronic-disease risk. Friends matter too. The credible story is not that aging science is fake—it is that hype sells now, and proof takes longer.